Highest-materiality recent filing
Sabra Health Care REIT files investor presentation; content beyond title page not furnished
Presentation cover page dated May 28, 2026 provided; no financial or operational metrics included in available text.
Sabra Q1: EPS $0.16, AFFO $0.39; same-store NOI +14.4%; reiterates 2026 guidance
Net income $0.16/diluted share; FFO $0.37, Normalized FFO $0.38, AFFO $0.39, Normalized AFFO $0.39.
Sabra Q4 FFO $0.36 per share; guides 2026 Normalized FFO $1.49-1.53 midpoint up 4.9% YoY
Q4 2025 net income $0.11/diluted share; Normalized FFO $0.36; AFFO $0.37; Normalized AFFO $0.38.
Sabra appoints Darrin Smith as CIO, Secretary, EVP; Talya Nevo-Hacohen retires
Talya Nevo-Hacohen retired as CIO, Treasurer, EVP effective Dec 31, 2025; will remain in consulting role.
Sabra Q3 2025: Normalized FFO $0.36; raises managed senior housing target to 40% of NOI
Q3 Normalized FFO $0.36 per share; AFFO $0.37; Net income $0.09 diluted.
New equity distribution agreement allows issuance of up to $750M in common stock via agents and forward sellers.
Sabra Q2 Normalized FFO $0.37; invests $122M YTD; closes $500M term loan; updates FY guidance
Q2 Normalized FFO $0.37, Normalized AFFO $0.38, Net Income $0.27 per diluted share.
Sabra Health Care enters $500M term loan, redeems $500M 5.125% notes due 2026
Entered $500M unsecured term loan maturing July 30, 2030; accordion allows increase to $1B subject to conditions.
Sabra Health Care REIT to redeem $500M 5.125% Notes due 2026, refinance with term loan
Redemption of all $500M aggregate principal of 5.125% Senior Notes due 2026 on July 31, 2025.
Sabra Health Care REIT shareholders elect all seven director nominees at annual meeting
All seven director nominees elected, with Craig A. Barbarosh receiving 190.3M for / 5.3M against.
Sabra Q1 FFO $0.35, AFFO $0.37; same-store senior housing NOI up 16.9% YoY
Net income $0.17/diluted share, FFO $0.36, Normalized FFO $0.35, AFFO $0.37.
Sabra CIO Talya Nevo-Hacohen to retire Dec 31, 2025; Darrin Smith to succeed Jan 1, 2026
Talya Nevo-Hacohen (EVP/CIO/Treasurer) retires Dec 31, 2025; Darrin Smith (EVP-Investments) becomes CIO Jan 1, 2026.
Sabra Q4 2024 EPS $0.19; Normalized FFO $0.35; guides 2025 Normalized FFO $1.43-$1.46
Q4 net income $0.19/diluted share; Normalized FFO $0.35; AFFO $0.36.
Sabra director Clifton Porter II to step down at 2025 annual meeting
Porter notified board on Nov 7, 2024; will not stand for reelection at 2025 annual meeting.
Sabra Q3 FFO $0.34, raises 2024 normalized FFO midpoint; $100M in acquisitions
Q3 diluted EPS $0.13; Normalized FFO $0.35; AFFO $0.36.
Sabra Q2 2024 FFO $0.35; raises 2024 guidance; acquires $76M senior housing
Net income $0.10/diluted share; Normalized FFO $0.35; AFFO $0.36 per share.
All eight director nominees elected; highest votes for Ann Kono at 183.3M, lowest at 174.5M for Richard K. Matros.
Sabra Q1 Normalized FFO $0.34, AFFO $0.35; reiterates FY guidance; $0.30 dividend
Q1 per diluted share: Net income $0.11, Normalized FFO $0.34, AFFO $0.35.
Talya Nevo-Hacohen, the Company’s Executive Vice President, Chief Investment Officer and Treasurer, has decided to retire from Sabra, effective December 31, 2025
Darrin Smith, Sabra’s Executive Vice President – Investments, is expected to assume this position effective January 1, 2026.
On November 7, 2024, Clifton J. Porter II notified the Board of Directors of Sabra Health Care REIT, Inc. (the “Company”) of his decision not to stand for reelection to the Company’s Board of Directors at the Company’s 2025 annual meeting of shareholders.
Max materiality 0.75 · Median 0.62 · Most common event earnings